Mergers and Acquisitions
bianca33
JohnsonJohnson.xlsxBenchmarking Analysis
| Benchmarking Analysis (Page 1) | ||||||||
| Company | Equity Value | Enterprise Value | Sales | Gross Profit | EBITDA | EBIT | Net Income | |
| Johnson & Johnson | 161.3 | 429.66B | 82.6B | 54.16B | 27.7B | 20.46B | 14.7B | |
| Pharmaceutical Companies | ||||||||
| Pfizer | 41.49 | 255.95B | 41.91B | 29.84B | 13.80B | 9.02B | 6.99B | |
| Moderna | 324.21 | 115.77B | 7.02B | -5.75 | 3.92B | 3.83B | 3.5B | |
| Benchmarking Analysis (Page 2) | ||||||||
| Company | Ticker | FYE | Predicted Beta | ROIC | ROE | ROA | Implied Div.Yield | Credit Ratings |
| Johnson & Johnson | JNJ | 31-Dec | 0.72 | 5.61% | 2.16% | 8.93% | N/A | Aaa |
| Pharmaceutical Companies | ||||||||
| Pfizer | PFE | 31-Dec | 0.69 | 6.82% | 27.00% | 5.04% | N/A | A2 |
| Moderna | MRNA | 31-Dec | 1.49 | 58.90% | -16.74% | -39.99 | N/A | Baa3 |
Companies Analysis
| Comparable Companies Analysis | ||||
| Company | Current Share Price | % of 52 Wk High | Equity Value | Enterprise Value |
| Johnson & Johnson | 161.3 | 74% | 69.58B | 429.66B |
| Pharmaceutical Companies | ||||
| Pfizer | 41.49 | 43% | 249.49B | 255.95B |
| Moderna | 324.21 | 43% | 6.704B | 115.77B |
